Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.

Detalles Bibliográficos
Autores principales: Mayence, Annie, Vanden Eynde, Jean Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469186/
https://www.ncbi.nlm.nih.gov/pubmed/30871014
http://dx.doi.org/10.3390/ph12010037
_version_ 1783411595596005376
author Mayence, Annie
Vanden Eynde, Jean Jacques
author_facet Mayence, Annie
Vanden Eynde, Jean Jacques
author_sort Mayence, Annie
collection PubMed
description In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.
format Online
Article
Text
id pubmed-6469186
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64691862019-04-24 Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases Mayence, Annie Vanden Eynde, Jean Jacques Pharmaceuticals (Basel) Brief Report In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes. MDPI 2019-03-12 /pmc/articles/PMC6469186/ /pubmed/30871014 http://dx.doi.org/10.3390/ph12010037 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Mayence, Annie
Vanden Eynde, Jean Jacques
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
title Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
title_full Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
title_fullStr Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
title_full_unstemmed Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
title_short Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
title_sort baricitinib: a 2018 novel fda-approved small molecule inhibiting janus kinases
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469186/
https://www.ncbi.nlm.nih.gov/pubmed/30871014
http://dx.doi.org/10.3390/ph12010037
work_keys_str_mv AT mayenceannie baricitiniba2018novelfdaapprovedsmallmoleculeinhibitingjanuskinases
AT vandeneyndejeanjacques baricitiniba2018novelfdaapprovedsmallmoleculeinhibitingjanuskinases

Ejemplares similares